Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

Fresh off winning a Nobel Prize last year, and previously tackling antibodies and peptides, the University of Washington’s ...

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.

The Vancouver-based company uses generative AI to create biologic drugs, with 20 “active programs” underway, many of them ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

The Institute for Protein Innovation (IPI), a nonprofit research institute dedicated to advancing protein science, today announced that it received a $500,000 grant from the Chan Zuckerberg Initiative ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...